Revance Therapeutics, Inc. (RVNC)

Revance Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	253	772	1,519	1,172	1,886	732
Market Cap Growth	-83.73%	-49.18%	29.62%	-37.87%	157.61%	-1.67%
Enterprise Value	451	996	1,597	1,266	1,658	471
PE Ratio	-	-2.38	-4.26	-4.16	-6.69	-4.59
PS Ratio	1.07	3.30	11.46	15.06	123.07	1772.66
PB Ratio	-4.40	-5.09	120.54	17.11	5.04	3.25
P/FCF Ratio	-1.97	-3.45	-7.72	-5.05	-10.33	-6.69
P/OCF Ratio	-2.04	-3.56	-7.85	-5.29	-10.57	-6.90
EV/Sales Ratio	1.91	4.26	12.04	16.27	108.20	1139.48
EV/EBITDA Ratio	-2.20	-3.43	-5.32	-4.96	-6.39	-3.01
EV/EBIT Ratio	-2.13	-3.27	-4.71	-4.60	-6.15	-2.95
EV/FCF Ratio	-2.86	-4.46	-8.11	-5.46	-9.08	-4.30
Debt / Equity Ratio	-4.82	-3.16	33.21	4.74	0.57	0.13
Debt / EBITDA Ratio	-1.65	-1.65	-1.39	-1.27	-0.82	-0.19
Debt / FCF Ratio	-2.16	-2.14	-2.13	-1.40	-1.16	-0.27
Quick Ratio	4.46	3.16	4.65	3.47	7.25	7.10
Current Ratio	5.37	3.80	4.95	3.66	7.38	7.24
Asset Turnover	0.45	0.43	0.21	0.13	0.02	0.00
Interest Coverage	-14.76	-15.72	-20.59	-43.84	-17.80	-
Return on Equity (ROE)	385.00%	502.90%	-786.70%	-181.70%	-86.10%	-81.10%
Return on Assets (ROA)	-60.00%	-60.10%	-57.10%	-46.30%	-43.40%	-52.00%
Return on Capital (ROIC)	-81.03%	-96.92%	-79.33%	-69.90%	-46.58%	-64.54%
Earnings Yield	-125.55%	-41.97%	-23.47%	-24.01%	-14.96%	-21.78%
FCF Yield	-87.33%	-28.95%	-12.96%	-19.79%	-9.68%	-14.94%
Buyback Yield / Dilution	-13.29%	-16.35%	-7.71%	-16.37%	-33.47%	-20.15%
Total Shareholder Return	-13.29%	-16.35%	-7.71%	-16.37%	-33.47%	-20.15%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).